If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

Share Price is delayed by 15 minutes
Get Live Data
26.25    -0.25 (-0.94%)
Bid:
26.00
Ask:
26.50
Spread: 0.50 (1.923%)
Market Cap: £132.17m
DUKE Live PriceLast checked at - London Stock Exchange

Intraday Duke Capital Share Chart

Trading and Operational Update

31 Mar 2026 07:00

RNS Number : 7112Y
Duke Capital Limited
31 March 2026
 

31 March 2026

Duke Capital Limited

 

("Duke Capital", "Duke" or the "Company")

 

Trading and Operational Update

 

Duke Capital Limited (AIM: DUKE), a leading provider of hybrid capital solutions for SME business owners in Europe and North America, is pleased to provide guidance on its trading for the fourth quarter of the financial year ending 31 March 2026 ("Q4 FY26").

 

Trading Update

 

Duke expects to achieve record recurring cash revenue* of £7.0 million in Q4 FY26. This represents an 8% year-on-year increase on Q4 FY25 (£6.5 million) and an increase of £0.2 million over the prior quarter, which saw the Company deliver recurring cash revenue of £6.8 million.

 

Total cash revenue for Q4 FY26 is expected to total £8.5 million following receipt of the final tranche of deferred consideration from the Fabrikat exit in February 2024.

 

Overview of quarterly revenue growth:

 

 

Recurring Cash Revenue*

Total Cash Revenue**

Q4 FY25

£6.5 million

£6.5 million

Q1 FY26

£6.6 million

£6.6 million

Q2 FY26

£6.6 million

£6.6 million

Q3 FY26

£6.8 million

£6.8 million

Q4 FY26 forecast

£7.0 million

£8.5 million

 

* Recurring cash revenue excludes exit premium receipts and cash gains from equity sales

** Total cash revenue is monthly cash distributions from Duke's partners plus exit premium receipts and cash gains from equity sales

 

Fabrikat exit

 

· Duke invested £6.2 million into Fabrikat in February 2021 and received £3.2 million in distributions until the sale of the company in March 2024 to Metalogalva - Irmãos Silvas, SA, a Portuguese company in the area of engineering and steel protection.

· Upon sale, Duke received total proceeds of £11.4 million, including £1.5 million in deferred payments, which resulted in a 35% IRR over a five-year period.

 

Neil Johnson, CEO of Duke Capital, said:

 

"We are delighted to report another record quarter of recurring cash revenue for Q4 FY26, rounding off a strong finish to the financial year. This performance reflects the resilience of our business model in navigating a challenging macroeconomic environment. Whilst the Bank of England's decision to hold rates in March reflects the ongoing uncertainty in global markets, including the situation in the Middle East, our business model has demonstrated its ability to perform across market cycles.

 

"The receipt of the final deferred consideration from the Fabrikat exit demonstrates our ability to provide upside for shareholders upon exits. While exits are expected in our business model, the timing of them is dependent on the broader fundraising environment. We are pleased to show both the resilience of our recurring revenue and upside from exits in the current quarter, and we look forward to updating shareholders further in our annual results."

 

 

***ENDS***

 

For further information, please visit https://dukecapital.com/ or contact:

 

Duke Capital Limited

Neil Johnson / Charles Cannon Brookes / Hugo Evans

 

+44 (0) 1481 231 816

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Stephen Keys / Callum Davidson / Michael Johnson 

+44 (0) 207 220 0500

 

Canaccord Genuity Limited

(Joint Broker)

 

Adam James / Harry Rees

+44 (0) 207 523 8000

SEC Newgate (Financial Communications)

Robin Tozer / Alice Cho / Gwen Samuel

+ +44 (0) 20 3757 6882 dukecapital@secnewgate.co.uk

 

 

About Duke Capital

 

Duke is a leading provider of hybrid capital solutions for SME business owners in Europe and North America, combining the best features of both equity and debt.

 

Since 2017, Duke has provided unique long-term financing which eliminates re-financing risk and necessity for a short-term exit by providing a unique 'corporate mortgage' while also aligning its returns to grow with the success of the business.

 

Duke is focused on generating attractive risk-adjusted returns for shareholders and has a track record of achieving this across market cycles. Its three investment pillars are capital preservation, attractive dividend yield, and to provide upside upon exits.

 

Duke is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTAKKBQFBKDCNN
Date   Source Headline
24th Mar 20172:55 pmRNSHolding(s) in Company
23rd Mar 20175:00 pmRNSRe-Admission and First Day of Dealings
22nd Mar 20173:45 pmRNSSch 1 Update - Duke Royalty Limited
20th Mar 20179:35 amRNSSch 1 Update - Duke Royalty Limited
17th Mar 20176:17 pmRNSResult of Fundraising
16th Mar 20175:03 pmRNSProposed Placing and Subscription
21st Feb 201711:25 amRNSSch 1 Update - Duke Royalty Limited
1st Feb 201711:00 amRNSSchedule 1 - Duke Royalty Limited
11th Jan 20177:01 amRNSAppointment of Chief Investment Officer
11th Jan 20177:00 amRNSChange of Advisors and Operational Update
17th Nov 20169:00 amRNSUnaudited interim results
1st Sep 201612:02 pmRNSResult of AGM
25th Jul 20167:00 amRNSFinal Results
29th Mar 20161:32 pmRNSSale of investments
7th Mar 20167:00 amRNSBoard Changes and Corporate Update
3rd Feb 20167:00 amRNSDirector/PDMR Shareholding
19th Jan 20169:55 amRNSChange of Adviser
14th Dec 201511:40 amRNSDirector/PDMR Shareholding
23rd Nov 20157:00 amRNSInterim results
29th Oct 20157:00 amRNSHolding(s) in Company
29th Oct 20157:00 amRNSCorrection: Appointment and Issue of Shares
28th Oct 20157:00 amRNSMr Justin Cochrane Appointment and Issue of Shares
12th Oct 20155:16 pmRNSHolding(s) in Company
17th Sep 20153:40 pmRNSFormation of Healthcare Investment Committee
14th Sep 201512:41 pmRNSHolding(s) in Company
11th Sep 20157:00 amRNSDirector share purchase
10th Sep 201512:00 pmRNSResult of AGM
7th Sep 20159:15 amRNSGrant of options
7th Sep 20157:00 amRNSPlacing
7th Sep 20157:00 amRNSCollaboration with Oliver Wyman
4th Aug 201512:21 pmRNSChanges to NAV Reporting
27th Jul 20154:12 pmRNSResults for the year ended 31 March 2015
16th Jun 201511:36 amRNSResult of EGM
10th Jun 201511:21 amRNSHolding(s) in Company
2nd Jun 20151:57 pmRNSHolding(s) in Company
28th May 201511:00 amRNSEGM, proposed changes to board & investing policy
26th May 20159:58 amRNSHolding(s) in Company
26th May 20159:57 amRNSHolding(s) in Company
26th May 20159:56 amRNSHolding(s) in Company
26th May 20159:56 amRNSHolding(s) in Company
22nd May 20155:15 pmRNSRepayment of zero dividend preference shares
20th May 20157:00 amRNSPlacing
15th May 201511:08 amRNSSale of investment
20th Apr 20155:36 pmRNSNet Asset Value(s)
19th Jan 20154:27 pmRNSNet Asset Value(s)
30th Dec 20143:07 pmRNSInterim Results
9th Dec 20145:23 pmRNSNet Asset Value
3rd Nov 20147:00 amRNSChange of administrator and registered address
22nd Oct 20147:00 amRNSNet Asset Value(s)
20th Aug 20141:54 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.